文献速递乳房整形与再造显微修复重建创面修复

一期腹壁下动脉穿支皮瓣挽救感染组织扩张器

One-Stage Deep Inferior Epigastric Perforator Flap Salvage of Infected Tissue Expanders.
PubMed 文献 · Ann Plast Surg · 2024-01-01

本文描述一种单期技术,对无全身性疾病的组织扩张器感染患者持续口服抗生素至DIEP皮瓣手术日,同期行扩张器取出、尝试全包膜切除和即刻DIEP皮瓣重建,术后口服抗生素1-2周。回顾性系列中6例培养证实的感染患者接受该方案,术后7-14天口服抗生素,90天内未见手术部位感染、微血管并发症、皮瓣部分丢失、再手术或重返手术室。作者认为经选择的患者中活动性感染扩张器可经单次游离皮瓣乳房重建挽救,需前瞻性研究评估该策略对费用、手术次数和不满意的影晌。

要点

  • 无全身性疾病的组织扩张器感染患者可维持口服抗生素至DIEP皮瓣手术日。
  • 单期行扩张器取出、尝试全包膜切除和即刻DIEP皮瓣重建,术后口服抗生素1-2周。
  • 6例培养证实的感染患者中,90天内未见手术部位感染、微血管并发症、皮瓣部分丢失、再手术或重返手术室。

核心结论

  • 在经选择的患者队列中,活动性感染的组织扩张器可通过单次手术的游离皮瓣乳房重建获得挽救,术后并发症发生率低。
  • 需要前瞻性研究评估该治疗策略对费用、手术次数以及因组织扩张器感染而复杂化的分期乳房重建后不满意的影响。

研究设计与样本

  • 回顾性系列,共纳入6例连续的患者,均为培养证实的组织扩张器感染,接受单期组织扩张器取出和DIEP皮瓣重建。
  • 患者无全身性疾病,维持口服抗生素至DIEP皮瓣手术日,术后口服抗生素7-14天。

主要发现

  • 6例患者均接受单期组织扩张器取出和DIEP皮瓣重建,术后口服抗生素7-14天。
  • 90天随访期内,未见手术部位感染、微血管并发症、皮瓣部分丢失、再手术或重返手术室。

临床怎么用

  • 作者描述的技术为:无全身性疾病的组织扩张器感染患者维持口服抗生素至DIEP皮瓣手术日,同期行扩张器取出、尝试全包膜切除和即刻DIEP皮瓣重建,术后口服抗生素1-2周并根据培养数据调整。
  • 作者认为在经选择的患者中,活动性感染的组织扩张器可通过单次手术的游离皮瓣乳房重建获得挽救,但需前瞻性研究进一步评估。

局限性

  • 本文为回顾性系列。
  • 样本为6例连续患者,样本量小。
  • 作者指出需要前瞻性研究评估该策略对费用、手术次数和不满意的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tissue expander-based breast reconstruction is associated with high rates of infectious complications, often leading to tissue expander explants and delays in receipt of definitive breast reconstruction and adjuvant therapy. In this study, we describe a single-stage technique where deep inferior epigastric artery perforator (DIEP) flaps are used to salvage actively infected tissue expanders among patients originally planning for free flap reconstruction. METHODS: In this technique, patients with tissue expander infections without systemic illness are maintained on oral antibiotics until the day of their DIEP flap surgery, at which time tissue expander explant is performed in conjunction with aggressive attempt at total capsulectomy and immediate DIEP flap reconstruction. Patients are maintained on 1-2 weeks of oral antibiotics tailored to culture data. Patients undergoing this immediate salvage protocol were retrospectively reviewed, and complications and length of stay were assessed. RESULTS: In a retrospective series, a total of six consecutive patients with culture-proven tissue expander infections underwent tissue expander removal and DIEP flap reconstruction in a single stage and were maintained on 7-14 days of oral antibiotics postoperatively. Within this cohort, no surgical site infections, microvascular complications, partial flap losses, reoperations, or returns to the operating room were noted within a 90-day period. CONCLUSIONS: Among a select cohort of patients, actively infected tissue expanders may be salvaged with free flap breast reconstruction in a single surgery with a low incidence of postoperative complications. Prospective studies are needed to evaluate the influence of this treatment strategy on costs, number of surgeries, and dissatisfaction after staged breast reconstruction complicated by tissue expander infections.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Sergesketter AR, Shammas RL, Tian WM, et al. One-Stage Deep Inferior Epigastric Perforator Flap Salvage of Infected Tissue Expanders. Ann Plast Surg. 2024. PMID: 38857007. doi:10.1097/SAP.0000000000003947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。